(3) the United States should support and en-
courage the carrying out of the agreements of the 
Group of 8 made at the 2005 Summit at Gleneagles, 
Scotland, to increase direct investment and create 
market incentives, including through public-private 
partnerships and advance market commitments, to 
complement public research in the development of 
vaccines, microbicides, and drugs for HIV/AIDS, 
malaria, tuberculosis, and other neglected diseases; 
(4) the United States should support testing of 
promising vaccines in infants, children, and adoles-
cents as early as is medically and ethically appro-
priate, in order to avoid significant delays in the 
availability of pediatric vaccines at the cost of thou-
sands of lives; 
(5) the United States should continue sup-
porting the work of the Global Alliance for Vaccines 
and Immunizations and the Global Fund for Chil-
dren’s Vaccines as appropriate and effective vehicles 
to purchase and distribute vaccines for neglected dis-
eases at an affordable price once such vaccines are 
discovered in order to distribute them to the devel-
oping world; and 
(6) the United States should work with others 
in the international community to address the mul-
tiple obstacles to the development of vaccines for ne-
glected diseases including scientific barriers, insuffi-
cient economic incentives, protracted regulatory pro-
cedures, lack of delivery systems for products once 
developed, liability risks, and intellectual property 
rights. 
SEC. 5. PUBLIC-PRIVATE PARTNERSHIPS. 
(a) FINDINGS.—Congress makes the following find-
ings: 
(1) Creative partnerships between governments 
and organizations in the private sector (including 
foundations, 
universities, 
corporations 
including 
pharmaceutical companies and biotechnology firms, 
community-based organizations and other non-
governmental organizations) are playing a critical 
role in the area of global health, particularly in the 
fight against neglected diseases, including HIV/ 
AIDS, tuberculosis, and malaria. 
(2) Public-private sector partnerships increase 
local and international capacities to improve the de-
livery of health services in developing countries and 
to accelerate research and development of vaccines 
and other preventive medical technologies essential 
to combating infectious diseases that disproportion-
ately kill people in developing countries.
(3) These partnerships maximize the unique ca-
pabilities of each sector while combining financial 
and other resources, scientific knowledge, and exper-
tise toward common goals which cannot be achieved 
by either sector alone. 
(4) Public-private partnerships such as the 
International AIDS Vaccine Initiative, the Malaria 
Vaccine Initiative, and the Global TB Drug Facility 
are playing cutting edge roles in the efforts to de-
velop vaccines for these diseases. 
(5) Public-private partnerships serve as incen-
tives to the research and development of vaccines for 
neglected diseases by providing biotechnology compa-
nies, which often have no experience in developing 
countries, with technical assistance and on the 
ground support for clinical trials of the vaccine 
through the various stages of development. 
(6) Sustaining existing public-private partner-
ships and building new ones where needed are essen-
tial to the success of the efforts by the United States 
and others in the international community to find a 
cure for these and other neglected diseases. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that—